What's Happening?
MaaT Pharma has announced plans to request a re-examination following a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its drug MaaT013, intended for treating acute Graft-versus-Host Disease (aGvHD). The CHMP's
decision was based on concerns about the attribution of clinical effects and safety to the treatment alone, given the use of concomitant therapies. MaaT Pharma intends to seek a Scientific Advisory Group hearing to provide further insights into the management of aGvHD. The company remains confident in the clinical profile of MaaT013, supported by data from studies and real-world evidence.
Why It's Important?
The decision by the CHMP impacts MaaT Pharma's ability to market MaaT013 in Europe, affecting its business strategy and potential revenue streams. For patients with aGvHD, the availability of effective treatments is crucial, as the condition can lead to severe complications and high mortality rates. The re-examination process will determine whether MaaT013 can be a viable treatment option, potentially offering a new line of therapy for patients who do not respond to existing treatments. The outcome will also influence the company's future research and development efforts in microbiome therapies.
What's Next?
MaaT Pharma will proceed with the re-examination process, which includes appointing new evaluators and potentially convening a Scientific Advisory Group. A new CHMP opinion is expected in September 2026. The company will continue its Early Access Program, providing MaaT013 to eligible patients. The outcome of the re-examination will guide MaaT Pharma's regulatory strategy and could impact its market presence in Europe. The company is also developing other microbiome therapies, which may provide alternative treatment options in the future.
